Abiraterone and Increased Survival in Metastatic Prostate Cancer

Johann S. de Bono, Christopher J. Logothetis, Arturo Molina, Karim Fizazi, Scott North, Luis Chu, Kim N., Robert J. Jones, Oscar B. Goodman, Fred Saad, John Staffurth, Paul N. Mainwaring, Stephen Harland, Thomas W. Flaig, Thomas E. Hutson, Tina Cheng, Helen Patterson, John D. Hainsworth, Charles J. Ryan, Cora N. Sternberg, Susan Ellard, Aude Fléchon, Mansoor N. Saleh, Mark C. Scholz, Eleni Efstathiou, Andrea Zivi, Diletta Bianchini, Yohann Loriot, Nicole Chieffo, Thian Kheoh, Christopher M. Haqq, Howard I. Scher

New England Journal of Medicine, 2011

Institute of Cancer Research, Royal Marsden NHS Foundation Trust, Royal Marsden Hospital, The University of Texas MD Anderson Cancer Center, Los Angeles City College, Institut Gustave Roussy, Cancer Institute (WIA), Hematology Oncology Consultants, BC Cancer Agency, Université de Montréal, Velindre Cancer Centre, Velindre NHS Trust, Cardiff University, Australasia Paediatric Endocrine Group, University College London, CRUK Lung Cancer Centre of Excellence, University of Colorado Cancer Center, University of Colorado Denver, Texas Oncology, University of Calgary, Sarah Cannon Research Institute, Sarah Cannon, UCSF Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, Nini Hospital, Centre Léon Bérard, Georgia Cancer Specialists, Oncology Specialists, Memorial Sloan Kettering Cancer Center, Cornell University

View Free PDF Publisher Website

Abstract

This research paper explore the methodology and findings associated with New England Journal of Medicine. The study delves into the core aspects of the research field, providing significant data and citation impact. (Full abstract processing is available via the OpenAlex API).

4371

Citations

View on Google Scholar

Abiraterone and Increased Survival in Metastatic Prostate Cancer

Abstract

Journal Details

Join JournalsHub

Welcome Back